Venus Concept Inc.
2.1800+0.05 (+2.35%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · VERO · USD
Key Stats
Market Cap
4.05MP/E (TTM)
-Basic EPS (TTM)
-44.79Dividend Yield
0%Recent Filings
8-K
Venus swaps $11.1M debt for equity
Venus Concept swapped $11.1 million in convertible notes for 545,335 Series Y preferred shares with Madryn on September 30, 2025, slashing total debt to $30.1 million—a 24% drop from year-end 2024. This exchange, priced at $21.05 per share based on recent common stock averages, bolsters the balance sheet amid market headwinds. Lenders also waived liquidity covenants through October 31 and extended bridge loan maturity to that date while hiking delayed draw commitments to $26 million. Debt relief sharpens focus on growth and profitability.
8-K
Lender consents extend liquidity relief
Venus Concept secured lender consents on August 31, 2025, waiving minimum liquidity covenants through September 30 across its MSLP loan, bridge loan, and 2025 notes, while extending the bridge loan maturity to September 30 and opting for PIK interest on September 8. This buys a month's breathing room amid liquidity strains, yet signals persistent cash flow pressures. Lenders hold firm on other terms. Relief ends soon.
8-K
Eleventh $2M drawdown funded
Venus Concept drew down $2 million under its bridge financing agreement with Madryn Health Partners on August 21, 2025, marking the eleventh such advance and pushing total borrowings to $23.2 million at 12% interest. Secured by all company assets, this infusion bolsters working capital amid ongoing needs. Yet liquidity remains tied to repayment terms.
8-K
Q2 revenue dips 5%, loss narrows
Venus Concept reported Q2 2025 revenue of $15.7 million, down 5% year-over-year but up 15% sequentially, with U.S. sales rising 5% on stronger cash systems demand while international dropped 18%. The company narrowed its GAAP net loss to $11.7 million from $19.9 million, amid gross margin compression to 60.1% from 71.5% due to economic uncertainty and supply disruptions. It advanced strategic moves, including a $20 million all-cash sale of its Venus Hair business to MHG Co. Ltd and $17.5 million in debt-to-equity conversions, bolstering the balance sheet yet flagging no 2025 guidance amid lender talks.
10-Q
Q2 FY2025 results
Venus Concept's Q2 FY2025 revenue dipped 5.4% y/y to $15.7M, with systems deliveries up 6.3% to 236 units yet squeezed by tighter credit and supply hiccups from the Israel-Iran clash; gross margin slipped to 60.1% from 71.5% on adverse mix and fixed costs over lower volume. Operating loss widened to $9.0M from $5.6M, driven by higher sales commissions and bad debt, while net loss narrowed to $11.7M from $19.9M thanks to a $1.9M debt swap gain and lower finance costs. Cash burned $11.8M in operations (up from $4.2M y/y), offset by $9.3M bridge draws and $3.3M equity raise, leaving $4.9M liquidity against $34.3M debt maturing 2026; free cash flow not disclosed in the 10-Q. A $20M all-cash hair unit sale to Meta, eyed for Q3 close, could sharpen focus on aesthetics. Tighter lending curbs customer buys.
AIRS
AirSculpt Technologies, Inc.
10.90-0.67
BVS
Bioventus Inc.
6.77-0.17
CERS
Cerus Corporation
1.45-0.05
CNMD
CONMED Corporation
46.71-0.61
EMED
Electromedical Technologies, In
0.00+0.00
INMD
InMode Ltd.
14.92-0.35
NVNO
enVVeno Medical Corporation
0.72+0.00
SNWV
SANUWAVE Health, Inc.
30.44-0.60
TMCI
Treace Medical Concepts, Inc.
6.55-0.29
VVOS
Vivos Therapeutics, Inc.
2.67+0.07